Terms: = Liver cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Diagnosis
18 results:
1. Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.
Zhang L; Su K; Liu Q; Li B; Wang Y; Cheng C; Li Y; Xu C; Chen J; Wu H; Zhu M; Mai X; Cao Y; Peng J; Yue Y; Ding Y; Yu D
BMC Cancer; 2023 Nov; 23(1):1081. PubMed ID: 37946141
[TBL] [Abstract] [Full Text] [Related]
2. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S
BMC Cancer; 2023 Sep; 23(1):908. PubMed ID: 37752423
[TBL] [Abstract] [Full Text] [Related]
3. Primary and secondary angiosarcomas of the liver: a multi-institutional study of 32 cases.
Liao X; Lai J; Lin J; Zhang D
Hum Pathol; 2023 Jul; 137():10-17. PubMed ID: 37054784
[TBL] [Abstract] [Full Text] [Related]
4. Three case reports: Temporal association between tyrosine-kinase inhibitor-induced hepatitis and immune checkpoint inhibitors in renal cell carcinoma.
Carretero-González A; Salamanca Santamaría J; Castellano D; de Velasco G
Medicine (Baltimore); 2019 Nov; 98(47):e18098. PubMed ID: 31764847
[TBL] [Abstract] [Full Text] [Related]
5. Renal Cell Carcinoma With Extensive Tumor Thrombus Into the Inferior Vena Cava and Right Atrium in a 70-Year-Old Man.
Oltean MA; Matuz R; Sitar-Taut A; Mihailov A; Rednic N; Tantau A; Toganel R; Minciuna IA; Orasan O; Muresan F; Cozma A
Am J Mens Health; 2019; 13(3):1557988319846404. PubMed ID: 31046582
[TBL] [Abstract] [Full Text] [Related]
6. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract] [Full Text] [Related]
7. MiR-139-5p regulates vegfr and downstream signaling pathways to inhibit the development of esophageal cancer.
Jiao W; Zhang J; Wei Y; Feng J; Ma M; Zhao H; Wang L; Jiao W
Dig Liver Dis; 2019 Jan; 51(1):149-156. PubMed ID: 30245290
[TBL] [Abstract] [Full Text] [Related]
8. Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without kdr mutation: A case report.
Rosati G; Del Gaudio N; Scarano E; Cifarelli RA; Altucci L; Bilancia D
Medicine (Baltimore); 2018 Jun; 97(25):e11178. PubMed ID: 29924031
[TBL] [Abstract] [Full Text] [Related]
9. Characterizing key nucleotide polymorphisms of hepatitis C virus-disease associations via mass-spectrometric genotyping.
Horiuchi Y; Lin J; Shinojima Y; Fujiwara K; Moriyama M; Nagase H
Int J Oncol; 2018 Feb; 52(2):441-452. PubMed ID: 29207078
[TBL] [Abstract] [Full Text] [Related]
10. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma.
Wang W; Jia WD; Hu B; Pan YY
Oncotarget; 2017 Apr; 8(16):26434-26447. PubMed ID: 28460436
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma.
Costache MI; Iordache S; Costache CA; Dragos E; Dragos A; Saftoiu A
J Gastrointestin Liver Dis; 2017 Mar; 26(1):51-57. PubMed ID: 28338114
[TBL] [Abstract] [Full Text] [Related]
12. CCL24 contributes to HCC malignancy via RhoB- VEGFA-vegfr2 angiogenesis pathway and indicates poor prognosis.
Jin L; Liu WR; Tian MX; Jiang XF; Wang H; Zhou PY; Ding ZB; Peng YF; Dai Z; Qiu SJ; Zhou J; Fan J; Shi YH
Oncotarget; 2017 Jan; 8(3):5135-5148. PubMed ID: 28042950
[TBL] [Abstract] [Full Text] [Related]
13. vegfr-2 expression in HCC, dysplastic and regenerative liver nodules, and correlation with pre-biopsy Dynamic Contrast Enhanced CT.
Thaiss WM; Kaufmann S; Kloth C; Nikolaou K; Bösmüller H; Horger M
Eur J Radiol; 2016 Nov; 85(11):2036-2041. PubMed ID: 27776657
[TBL] [Abstract] [Full Text] [Related]
14. Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Dana P; Fujikawa S; Matsuda K; Ohkuma K; Kudo E; Kraiklang R; Wongkham C; Wongkham S; Okada S
Tumour Biol; 2016 Jul; 37(7):9023-35. PubMed ID: 26762407
[TBL] [Abstract] [Full Text] [Related]
15. Novel molecular targets for diagnosis and treatment of hepatocellular carcinoma.
Ma L; Ji L; Yu Y; Wang J
Discov Med; 2015 Jan; 19(102):7-14. PubMed ID: 25636956
[TBL] [Abstract] [Full Text] [Related]
16. Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma.
Zhang YS; Chu JH; Cui SX; Song ZY; Qu XJ
Cell Physiol Biochem; 2014; 34(3):903-15. PubMed ID: 25200250
[TBL] [Abstract] [Full Text] [Related]
17. Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management.
Emamaullee JA; Edgar R; Toso C; Thiesen A; Bain V; Bigam D; Kneteman N; Shapiro AM
Liver Transpl; 2010 Feb; 16(2):191-7. PubMed ID: 20104492
[TBL] [Abstract] [Full Text] [Related]
18. Growth factors as therapeutic targets in HCC.
Furuse J
Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
[TBL] [Abstract] [Full Text] [Related]
